Mohamed Abdelaziz: Atezolizumab and Bevacizumab versus Sorafenib in Egyptian HCC patients

Mohamed Abdelaziz: Atezolizumab and Bevacizumab versus Sorafenib in Egyptian HCC patients

Mohamed Abdelaziz, National Oncology Committee member at Ministry of Health and Population in Egypt and Intern Fellow at Gustave Roussy, shared on LinkedIn:

“Thrilled to share the publication of our recent poster presented in ESMO ASIA.

Tackling the benefit of atezo/beva vs sorafenib in Egyptian HCC patients.”

235P Combined atezolizumab and bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: A single center experience

Authors: A.A. Khalil, M.A. Abdelaziz, T.I. El Nahas

Mohamed abdelaziz
Further Reading:

Highlights from Day 1 of ESMO Asia 2024

Highlights from Day 2 of ESMO Asia 2024

Highlights from Day 3 of ESMO Asia 2024

Best of ESMO Asia 2024

Abdallah Khalil Atezolizuma Bevacizumab cancer ESMO Asia 2024 Hepatocellular carcinoma (HCC) Mohamed Abdelaziz OncoDaily Oncology sorafenib Tamer El Nahas